Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 2Gastrointestinal 2Head & Neck 1CNS 1

Conditions

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × amivantamab × Gastrointestinal × Clear all
NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting
197 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06855849 2025-03-04

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

Yonsei University

Phase 2 Not yet recruiting
85 enrolled
Gastrointestinal

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡